Immunotherapy

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalised viral vector-based cancer vaccines, has raised €67.5 million in an oversubscribed Series C financing round. The proceeds will enable Nouscom to advance its pipeline and complete Phase II clinical trials with its cancer vaccine NOUS-209. Representatives from Andera Partners, Bpifrance and M Ventures, who led […]

Don’t forget to register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading international figures. The event, which will be sponsored by Taconic Biosciences, will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET and […]

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. On Day 3, Thursday 16 November 2023, the tracks include: the second part of machine learning for protein engineering, antibodies against membrane protein targets, engineering bispecific […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug […]

News round-up for 6-10 November by DDW Digital Content Editor Diana Spencer. With the first DDW Turning Science into Business Summit taking place next week on the theme of Cancer Research, this dynamic area of drug discovery is my round-up focus again. Most significantly, this week has seen the UK approval of a new indication […]

The Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting (SITC 2023) took place on 1-5 November 2023, at San Diego Convention Center in San Diego, US. CAN-2409 in non-metastatic pancreatic cancer Candel Therapeutics reported on initial positive interim data from its Phase II clinical trial of CAN-2409 that showed notable improvements in patients with […]

DDW Editor Reece Armstrong speaks to Christian Leisner, Chief Executive Officer of antibody therapeutics’ developer CDR-Life about methods to increase access to antigens and improving immunotherapy treatments. RA: Why are existing immunotherapies restricted to certain patient populations?  CL: Immunotherapies, principally anti-PD-1/-L1 checkpoint inhibitors, have shown therapeutic benefit in improving the prognosis of patients but only […]

Initial data from an ongoing Phase I/II study of HPK1 inhibitor NDI-101150 show clinical benefit in three patients with solid tumours, including one complete response in a patient with renal cell carcinoma. Two patients with pancreatic cancer and renal cell carcinoma, respectively, exhibited prolonged (> six months) stable disease. NDI-101150 demonstrated an acceptable safety profile […]

Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET and […]

The latest in the DDW eBook series ‘Immunotherapy: Where are the advances and breakthroughs?‘ is now available for download. This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for […]

This 24-page eBook sponsored by Sino Biological looks at the advances and breakthroughs taking place within immunotherapy. Download this exclusive eBook to learn more about: Advances in cancer care: Where are the advances in treatments for triple-negative breast cancer? Drug development: Five years of oncology developments Why immunotherapy is here to stay Precision cancer therapies: […]

Register for the DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, to hear insight and expertise from leading figures. It will be hosted by DDW and sponsored by Taconic Biosciences. The event will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET and […]

This is the latest episode of the free DDW narrated podcast, “Drug discovery success stories”, which covers two articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Global pharma start-up success stories”, and “Excitement at rectal cancer immunotherapy breakthrough”. In the first article, Lu Rahman selects some interesting global […]

Join DDW’s Megan Thomas and Reece Armstrong with sponsor Taconic Biosciences for the first DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’, on 16 November at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. This free 2-hour Summit will take place online and will outline areas of advancement and […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, […]

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. Immunotherapy has taken centre stage this week, with several announcements relating to regulatory approval, investment and research results for antibody and CAR-T therapies, perhaps most significantly, encouraging early-stage data for the first in vivo CAR-T therapy. The top stories: €27.3M to advance monoclonal […]